Stockwinners Market Radar for December 07, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EST Cathie Wood's ARK Investment bought 106K shares of Verve Therapeutics today

18:46 EST Campbell Soup CEO: The supply chain is now a 'real strength' - In an interview on CNBC's Mad Money, Mark Clouse said many of Campbell's brands are well-positioned in this inflationary environment. The range of its offerings is appealing to a broader audience, he noted. Clouse indicated that the supply chain is now a 'real strength' whereas previously it had been a challenge.

18:24 EST Norfolk Southern CEO: We're focused on service - In an interview on CNBC's Mad Money, Alan Shaw said, "Our focus on service is a competitive advantage." The company is targeting the trucking and logistics market, he noted. Shaw is seeing a trend towards onshoring amid geopolitical and energy risk, and is "really confident" about Norfolk Southern's future.

18:04 EST Puma Biotechnology presents updated findings from TBCRC-022 trial - Puma Biotechnology presented updated findings from the Translational Breast Cancer Research Consortium Trial 022 at the ongoing 2022 San Antonio Breast Cancer Symposium in San Antonio, Texas. The poster, entitled "Neratinib and ado-Trastuzumab-Emtansine for HER2+ Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium Trial 022," was presented by Rachel A Freedman, MD, MPH, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana Farber Cancer Institute, at Spotlight Poster Session 7 on December 7 from 5:00 p.m. - 6:15 p.m. CT. TBCRC-022 is a prospective, multicenter, Phase II study to evaluate the effect of neratinib plus T-DM1 in patients with HER2-positive breast cancer brain metastases. This presentation outlined updates from three cohorts: 4A - patients with previously untreated BCBM; 4B - patients with BCBM progressing after prior local CNS-directed therapy without prior T-DM1 exposure; and 4C - patients with BCBM progressing after prior local CNS-directed therapy with previous T-DM1 exposure. Data from previous cohorts from this study were reported at the 2017 ASCO Annual Meeting. Patients with measurable HER2-positive BCBM received neratinib 160 mg orally once daily plus T-DM1 3.6 mg/kg intravenously every 21 days in the three parallel-enrolling cohorts. Diarrhea prophylaxis with colestipol and loperamide was required during cycle 1. All enrolled patients underwent a brain MRI plus CT scan of the chest/abdomen/pelvis every 6 weeks for 18 weeks, followed by every 9 weeks thereafter. The primary endpoint, Response Assessment in Neuro-Oncology-Brain Metastases, was evaluated in each cohort separately. The efficacy results from the trial showed that CNS Objective Response Rate by RANO-BM was 33.3% of patients in cohort 4A, 29.4% in cohort 4B, and 28.6% in cohort 4C. Rates of response + stable disease greater than or equal to 6 months were 50% in cohort 4A, 35.3% in cohort 4B, and 33.3% in cohort 4C. Intracranial activity was observed for the combination of neratinib plus T-DM1 in all three cohorts, including in patients with prior T-DM1 exposure, suggesting a reversal of resistance to T-DM1. Overall, the most frequently observed adverse event was diarrhea, grade 2 (32%) and grade 3 (23%). These data provide additional evidence for the consideration of neratinib-based combinations in patients with HER2-positive BCBM.

17:38 EST Esports Entertainment CEO Grant Johnson to leave company - Esports Entertainment announced the departure of Grant Johnson from his position as Chairman and Chief Executive Officer, effective December 3, 2022. The Board of Directors has identified several candidates to be the company's next CEO, and these candidates are currently going through the evaluation process. The company has identified a preferred candidate for interim/acting CEO, and will make a formal announcement naming this individual in the coming days pending a formal approval by the Nominating and Corporate Governance Committee. The company has also announced Jan Jones Blackhurst as Chair of the Board of Directors. "Grant recognized the value of esports and online gambling and founded EEG on that basis. On behalf of the Board, we wish him well," said Ms. Jones Blackhurst. "The Company is looking forward to bringing in new leadership to work with Board to realize the full potential of our acquired esports businesses."

17:11 EST Chevron announces 2023 organic capex budget of $14B - Chevron "announced 2023 organic capital expenditure budgets of $14B for consolidated subsidiaries (capex) and $3B for equity affiliates (affiliate capex), which total near the high end of the company's guidance range. The company's 2023 capex budget is up more than 25% from 2022 expected spend, excluding acquisitions. Affiliate capex in 2023 is down modestly from 2022 expected spend. These budgets support Chevron's objective to safely deliver higher returns and lower carbon and include approximately $2 billion in lower carbon capex, more than double the 2022 budget. Chevron's 2023 capex budget assumes cost inflation that averages in the mid-single digits with certain areas higher, such as the Permian Basin that assumes low double-digit cost inflation."

17:08 EST HashiCorp jumps 10% to $29.43 after Q3 earnings beat and guidance raise

17:01 EST UpHealth says reverse stock split to effect changes to warrant terms - UpHealth announced that the previously announced reverse stock split of the company's issued and outstanding common stock approved by its Board of Directors and the company's stockholders on December 5, 2022 whereby each ten shares of common stock will be combined and reconstituted into one share of common stock will effect proportionate adjustments to its outstanding warrants. The company's warrants, traded on the NYSE under the symbol UPH.WS, will be reduced at a ratio of 1-for-10. The exercise price of each warrant will increase from $11.50 per share to $115.00 per share.

17:00 EST Revolution to regain rights to RMC-4630 following Sanofi deal termination - Revolution Medicines (RVMD) announced that Sanofi (SNY) has provided notice of termination of the parties' global SHP2 development and commercialization collaboration. Following termination, Revolution Medicines will regain all global rights granted to Sanofi under the agreement, including decision-making regarding research and development, and rights to all commercial proceeds from RMC-4630, a SHP2 inhibitor drug candidate in development for the treatment of patients with certain RAS-addicted cancers. The companies plan to collaborate to transition all Sanofi's rights and obligations related to RMC-4630 back to Revolution Medicines over the first half of 2023. "We remain committed to studying RMC-4630 as a potentially important RAS Companion Inhibitor in our cohesive pipeline focused on novel targeted therapies for RAS-addicted cancers, and fully intend to continue as planned our ongoing Phase 2 clinical trial evaluating RMC-4630 in combination with sotorasib for patients with NSCLC bearing a KRASG12C mutation," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "Going forward, our strategy for developing RMC-4630 is unaffected by their decision, and we continue to expect to provide topline data from our RMC-4630-03 study in the second half of 2023." Sanofi notified Revolution Medicines of its termination of the collaborative research, development and commercialization agreement for convenience on December 6, 2022. During the transition, Revolution Medicines expects that Sanofi will continue to fulfill any obligations under the Collaboration Agreement, including reimbursing Revolution Medicines' costs, as contemplated by the Collaboration Agreement. With current cash, cash equivalents and marketable securities, Revolution Medicines continues to project it can fund planned operations through 2024. The company is updating its projected full year 2022 GAAP net loss to be between $245M to $265M, including estimated non-cash stock-based compensation expense of $30M to $35M.

16:55 EST Sportsman's Warehouse falls 8% after Q3 results, below-consensus Q4 guidance

16:42 EST Eargo appoints new directors, chairman to board following rights offering - Eargo announced the appointments of several new directors following the closing of the company's rights offering as previously announced on November 29. Patient Square Capital became the company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors to the company's board of directors that is proportionate to its ownership of the company, and has nominated Karr Narula, Justin Sabet-Peyman, and Trit Garg to serve on the board, effective immediately. Sabet-Peyman will serve as chair of both the compensation committee and the nominating and corporate governance committee, and Garg will serve as a member of the compensation committee and the nominating and corporate governance committee. The appointment of the new Patient Square directors fills the seats vacated by Josh Makower, Douglas Hughes, and A. Brooke Seawell, following their respective resignations from the board. In addition, the company announced the appointment of Donald Spence to its board, also effective immediately. Spence will serve as chair of the board and will serve as a member of the audit committee. The board increased its size from six to seven members with the appointment of Spence.

16:36 EST Rapid Micro Biosystems publishes colony counting data in journal - Rapid Micro Biosystems announced the publication of a Multi-Author Case Study Supporting Fully Automated Colony Counting in Pharmaceutical Microbiology. This study, published online by the PDA Journal of Pharmaceutical Science and Technology, sought to evaluate colony counters as an automated compendial microbiological test method and references current regulatory guidelines. In order to simplify validation, all sites followed a modular validation approach that had been developed by the participants. The modular validation facilitates the efficient implementation of the technology to routine use while complying with regulatory requirements. This publication was produced by eight global pharmaceutical companies who implemented and validated an automated colony counting technology to perform quality control microbiology tests, environmental monitoring, bioburden and water testing, in-process product samples and bulk drug substance bioburden. The Growth Direct system has been successfully implemented for routine use in cGMP areas for all applications and QC test requirements mentioned, as well as in-process bioburden testing for new drug applications to the FDA and EMA.

16:35 EST Hall of Fame Resort & Entertainment receives $15.8M tax credit award - Hall of Fame Resort & Entertainment has received a $15.8M Transformational Mixed-Use Development - TMUD - tax credit award from the Ohio Tax Credit Authority and the Ohio Department of Development for the construction of its football-themed waterpark and Hilton Tapestry Hotel located at its Hall of Fame Village. The Ohio TMUD is designed to support the new construction and/or improvement of vacant buildings that will have a transformational economic impact on the site and the surrounding area. Hall of Fame Village received the highest amount the company was eligible for within its designated category under this highly competitive tax credit award program and was one of only 12 projects awarded for 2023.

16:32 EST My Size approves 1-for-25 reverse stock split - MySize has approved a one-for-twenty-five reverse stock split of its common stock that is scheduled to become effective after trading closes on December 8. Beginning on December 9, the company's common stock will trade on Nasdaq on a split adjusted basis under a new CUSIP number 62844N 307. The company's common stock will continue to trade on Nasdaq under the symbol "MYSZ." At the Annual Meeting of Stockholders on December 7, stockholders approved a reverse stock split at a ratio in the range of 1-for-10 to 1-for-30 in order to increase the per share price and bid price of the company's common stock to regain compliance with the continued listing requirements of Nasdaq and make the common stock more attractive to certain institutional investors, which would provide for a stronger investor base. The reverse stock split will not affect any stockholder's ownership percentage of the company's common stock, except to the extent that the reverse stock split would result in any stockholder owning a fractional share. Fractional shares of common stock will be rounded up to the nearest whole share. The number of authorized shares of the company's common stock will not change, while the number of outstanding shares will be reduced from approximately 36 million to approximately 1.5 million.

16:31 EST Genuine Parts names Will Stengel President and COO - Genuine Parts Company announced that its board of directors has appointed William Stengel to the position of president and COO and Christopher Galla to the position of senior vice president and general counsel, effective January 1, 2023. Stengel joined the company in 2019 as executive vice president and chief transformation officer with nearly two decades of significant leadership and professional experience. In 2021, he was promoted to serve as only the eighth president in the company's 93-year history. Galla has been with the company for nearly 18 years, and he was most recently vice president and general counsel, responsible for the company's legal function.

16:27 EST PDC Energy announces 65c per share special dividend - PDC Energy announced that its board of directors declared a special dividend of 65c per share in addition to a quarterly cash dividend of 35c per share on PDC's outstanding common stock. The dividends are payable on December 28 to stockholders of record at the close of business on December 19. For the FY22, PDC anticipates returning approximately $1B to shareholders through share repurchases, base dividend payments and the special dividend. Inclusive of the combined $1.00 base and special dividend payments in December and the $745M invested in share repurchases to retire approximately 11M shares through November 30, 2022, PDC has returned approximately $925M in 2022 so far. The company maintains an active share repurchase program and expects to continue to repurchase shares through year-end and into 2023 under its existing board-authorized $1.25B share repurchase program.

16:26 EST Sanofi terminates SHP2 Inhibitor development pact with Revolution Medicines - Revolution Medicines (RVMD) announced that Sanofi (SNY) has provided notice of termination of the parties' global SHP2 development and commercialization collaboration. Following termination, Revolution Medicines will regain all global rights granted to Sanofi under the agreement, including decision-making regarding research and development, and rights to all commercial proceeds from RMC-4630, a SHP2 inhibitor drug candidate in development for the treatment of patients with certain RAS-addicted cancers. The companies plan to collaborate to transition all Sanofi's rights and obligations related to RMC-4630 back to Revolution Medicines over the first half of 2023."We remain committed to studying RMC-4630 as a potentially important RAS Companion Inhibitor in our cohesive pipeline focused on novel targeted therapies for RAS-addicted cancers, and fully intend to continue as planned our ongoing Phase 2 clinical trial evaluating RMC-4630 in combination with sotorasib for patients with NSCLC bearing a KRASG12C mutation," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. " The company is updating its projected full year 2022 GAAP net loss to be between $245Mto $265M, including estimated non-cash stock-based compensation expense of $30M to $35M.

16:25 EST Greif falls 5% to $66.76 after Q4 results miss estimates

16:23 EST rie Indemnity increases Class A dividend 7.2% to $1.19 - Erie Indemnity increased the regular quarterly cash dividend to $1.19 from $1.11 on each Class A share and from $166.50 to $178.50 on each Class B share. This represents a 7.2% increase in the payout per share over the current dividend rate. The next quarterly dividend is payable Jan. 20, 2023, to shareholders of record as of Jan. 5, 2023, with a dividend ex-date of Jan. 4, 2023.

16:22 EST Park Hotels & Resorts declares Q4 dividend of 25c per share - Park Hotels & Resorts announced that the company has declared a fourth quarter cash dividend of 25c per share of common stock. The dividend will be paid in cash on January 17, 2023 to holders of record as of December 30, 2022. "Of the full 25c per share dividend, 12c per share represents the fourth quarter payment based on 2022 results of operations, while the remaining 13c per share is attributable to gains from the sale of Park's assets during 2022," the company stated.

16:19 EST 3D Systems appoints Dr. Brent Stucker Chief Technology Officer - 3D Systems announced that Dr. Joe Zuiker will join the company as Executive Vice President, Engineering and Operations, effective December 12. In addition, industry veteran Dr. Brent Stucker, who joined 3D Systems in 2021, is appointed Chief Technology Officer - Additive Manufacturing. Both positions will report directly to Dr. Jeffrey Graves, president and CEO of 3D Systems.

16:18 EST PBF Energy appoints Karen Davis as Interim CFO - PBF Energy has named Karen Davis Chief Financial Officer on an interim basis effective January 1, 2023. Davis previously served as Executive VP and CFO of Western Refining and its affiliated entities, Western Refining Logistics and Northern Tier Energy through May 2017. She has served in various chief financial officer and financial reporting officer positions with various public and private companies throughout the U.S. Davis has served as an independent director of PBF Energy since January 1, 2020 and the Chairperson of the Audit Committee since October 1, 2020. From 2017 through 2019, she served as a director of PBF Logistics LP, where she was a member of the Audit and the Conflicts Committees. In connection with the assumption of the duties of Interim CFO, Davis will step down from the Board of Directors of PBF Energy.

16:15 EST Moderna appoints Brad Miller Chief Information Officer - Moderna (MRNA) announced the appointment of Brad Miller as Chief Information Officer effective January 3. Mr. Miller will serve on Moderna's Executive Committee and report to Chief Executive Officer, Stephane Bancel. Marcello Damiani, who is currently serving in this role as Chief Digital Officer, will be retiring from the company after seven and a half years."I want to express my gratitude to Marcello for his significant contributions over the past seven and a half years. Marcello joined Moderna before our first clinical trial, and where we are today as a digital-first company is a testament to his leadership and ability to scale digital resources during periods of hypergrowth. At the same time, I want to welcome Brad to our team as Chief Information Officer and member of our Executive Committee," said Moderna Chief Executive Officer Stephane Bancel. "Brad comes to us with deep experience leveraging digital and IT solutions to solve complex business challenges, which will be particularly valuable as our company continues its rapid growth globally." Mr. Miller joins Moderna from Capital One (COF), where he served as Executive Vice President and Chief Information Officer. In this role, Mr. Miller led the company's Enterprise Products and Platforms organization, responsible for building and operating critical enterprise services and digital experiences across all lines of business. In addition to Capital One, Mr. Miller has also held technology leadership roles at Mastercard, where he served as Executive Vice President, Operations and Technology, and Citibank, where he was Head of Global Digital and Cloud Technology. Prior to his posts in the financial services industry, Mr. Miller spent more than 17 years in various engineering roles between Amazon and Microsoft.

16:12 EST SPX Technologies appoints Mark Carano CFO - SPX Technologies (SPXC) announced the appointment of Mark A. Carano as Vice President, Chief Financial Officer and Treasurer, effective January 3. Mr. Carano joins SPX Technologies with extensive executive experience in finance, accounting, strategy, and business development, including senior leadership roles in public companies.Mr. Carano joins SPX from Insteel Industries, Inc, a publicly-traded manufacturer of steel wire reinforcing products for concrete construction applications (IIIN), where he served as Senior Vice President, Chief Financial Officer and Treasurer.

16:11 EST Relmada Therapeutics' REL-1017 in depressive disorder did not reach endpoint - Relmada Therapeutics announced results of the RELIANCE I study evaluating REL-1017 as an adjunctive treatment for Major Depressive Disorder. The same factors that negatively affected the results from the RELIANCE III study, a limited number of high enrolling sites with unplausible placebo response, also affected RELIANCE I and the study did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo on Day 28. RELIANCE I evaluated the use of REL-1017 in addition to a standard antidepressant for patients who had inadequate response to at least one and up to three standard antidepressant therapies. In the study, the REL-1017 treatment arm showed a MADRS reduction of 15.1 points at Day 28 versus 12.9 points for the placebo arm, which is a clinically meaningful difference of 2.2 points on the MADRS, as well as a statistically significant difference in the response rate, with a response rate of 27.2% on placebo vs 39.8% in the REL1017 arm. As observed in the monotherapy study RELIANCE III, implausible results were again observed in two of the same high enrolling RELIANCE I study centers, where placebo dramatically outperformed REL-1017. A limited number of the same high enrolling centers had implausible rapid and sustained placebo response rates that outperformed REL1017. In a post-hoc analysis of RELIANCE 1 that excluded the same two high enrolling centers that showed implausible placebo response in both REL-1017 studies, the REL-1017 treatment arm showed a MADRS reduction of 16.7 points at Day 28 versus 12.6 points for the placebo arm, a 4.1 point difference, with a pless than0.02. REL-1017 demonstrated very favorable tolerability and safety in RELIANCE I, again confirming the results of Phase 1 and Phase 2. Relmada continues to enroll patients in RELIANCE II, the second ongoing Phase 3 study evaluating REL-1017 as a potential adjunctive treatment for MDD. Relmada is applying several protocol and operational changes to RELIANCE II.

16:07 EST Verint announces $250M share buyback

16:06 EST ROC Energy Acquisition confirms deadline extension for initial combination - ROC Energy Acquisition announced that an affiliate of ROC Energy Holdings - the "Sponsor" -, has deposited an aggregate of $2,070,000, representing 10c per public share, into the company's trust account for its public stockholders. This deposit enables the company to extend the date by which the company has to complete its initial business combination from December 6, 2022 to March 6, 2023. The extension is the first of two three-month extensions permitted under the company's governing documents. The affiliate of the Sponsor loaned the extension payment to the company. The loan is non-interest bearing and convertible, at the lender's discretion, into units identical to the units issued in the company's private placement that was consummated in connection with the company's IPO.

16:01 EST Relmada Therapeutics trading halted, news pending

15:54 EST Prelude Therapeutics trading halted, volatility trading pause

15:12 EST Ford reports chief marketing officer Deering departing company - Ford announced that Suzy Deering is departing the company effective Dec. 9. Deering has served as Ford's global chief marketing officer for the past two years, overseeing brand communication, ecommerce and digital strategy, as well as the go-to-market strategy for Ford Blue and while supporting the future vision of Model e. "We thank Suzy for her contributions to Ford and wish her all the best in the future," said Kumar Galhotra, president, Ford Blue. Ford said Deering's successor would be the subject of a future announcement. Reference Link

14:56 EST Sutro Biopharma pediatric acute myeloid leukemia treatment granted orphan status - Sutro Biopharma's luveltamab was granted orphan status by the FDA as a tazevibulin pediatric acute myeloid leukemia treatment, according to a post to the agency's website. Reference Link

14:18 EST BWX Technologies trading resumes

13:52 EST Deere raises dividend 6% to $1.20 per share - Deere & Company announced that its board of directors declared a quarterly dividend of $1.20 per share payable February 8, 2023, to stockholders of record on December 30, 2022. The new quarterly rate represents an additional 7c per share over the previous level, an increase of approximately 6% per share.

13:47 EST Apple introduces three new advanced data security features - Apple introduced three advanced security features focused on protecting against threats to user data in the cloud, representing the next step in its ongoing effort to provide users with even stronger ways to protect their data. With iMessage Contact Key Verification, users can verify they are communicating only with whom they intend. With Security Keys for Apple ID, users have the choice to require a physical security key to sign in to their Apple ID account. And with Advanced Data Protection for iCloud, which uses end-to-end encryption to provide Apple's highest level of cloud data security, users have the choice to further protect important iCloud data, including iCloud Backup, Photos, Notes, and more. "At Apple, we are unwavering in our commitment to provide our users with the best data security in the world. We constantly identify and mitigate emerging threats to their personal data on device and in the cloud," said Craig Federighi, Apple's senior vice president of Software Engineering. "Our security teams work tirelessly to keep users' data safe, and with iMessage Contact Key Verification, Security Keys, and Advanced Data Protection for iCloud, users will have three powerful new tools to further protect their most sensitive data and communications." Reference Link

13:36 EST BNY Mellon says NIR still stronger than anticipated, expects up 12% in Q4 - Speaking at the Goldman Sachs 2022 US Financial Services Conference, BNY Mellon's CFO Emily Portney said that, "our transaction activity is very healthy, and obviously, short-term interest rates continue to rise. So, with 3 weeks left in the quarter and assuming that market is more or less still steady where they are, we'd expect fee revenue for the fourth quarter to be flat to slightly down year-on-year, which would mean that fee revenue, overall, for the year will be roughly flat to last year. In terms of NIR, it continues to be stronger than we had anticipated... For the fourth quarter, we now expect NIR to be up about 12% sequentially. And what the pie for the year would be NIR north of 30% year-on-year. As far as expenses, excluding notable items, we intend, or we expect, expenses to be up about 1% sequentially. And that would imply that we are going to land the plane very much as we had suggested in the last earnings call, so the lower end of the 5% to 5.5% range year-on-year that we are driving... we've been very proactively managing our securities portfolio really to retain flexibility and optionality."

13:15 EST North American rail traffic down 1.7% for the week ending December 3 - The Association of American Railroads or AAR, reported U.S. rail traffic for the week ending December 3.Total U.S. weekly rail traffic was 495,472 carloads and intermodal units, down 6% compared with the same week last year. Total carloads for the week ending December 3 were 241,307 carloads, down 5.4% compared with the same week in 2021, while U.S. weekly intermodal volume was 254,165 containers and trailers, down 6.7% compared to 2021.Three of the 10 carload commodity groups posted an increase compared with the same week in 2021. They were coal, up 475 carloads, to 69,107; motor vehicles and parts, up 229 carloads, to 15,044; and farm products excl. grain, and food, up 94 carloads, to 17,709. Commodity groups that posted decreases compared with the same week in 2021 included chemicals, down 10,232 carloads , to 28,290; grain, down 2,018 carloads, to 26,212; and forest products, down 901 carloads, to 9,666. North American rail volume for the week ending December 3, on 12 reporting U.S., Canadian and Mexican railroads totaled 344,150 carloads, down 0.6% compared with the same week last year, and 333,927 intermodal units, down 2.8% compared with last year. Total combined weekly rail traffic in North America was 678,077 carloads and intermodal units, down 1.7%. North American rail volume for the first 48 weeks of 2022 was 32,505,576 carloads and intermodal units, down 1.9 percent compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP), FreightCar America (RAIL), Trinity Industries (TRN), Greenbrier (GBX) and Wabtec (WAB). Reference Link

12:00 EST Deutsche X-trackers MSCI EAFE Hedged Equity ETF falls -12.3% - Deutsche X-trackers MSCI EAFE Hedged Equity ETF is down -12.3%, or -$4.63 to $33.08.

12:00 EST Carvana falls -36.1% - Carvana is down -36.1%, or -$2.42 to $4.29.

12:00 EST State Street rises 9.0% - State Street is up 9.0%, or $6.68 to $81.04.

11:55 EST Microsoft enters 10-year deal to bring 'Call of Duty' to Nintendo, Steam - Microsoft Gaming (MSFT) CEO Phil Spencer said that the company has entered into a 10-year commitment to bring "Call of Duty" to Nintendo (NTDOY) following the merger of Microsoft and Activision Blizzard (ATVI). "Microsoft is committed to helping bring more games to more people - however they choose to play," Spencer said. He added that Microsoft has committed to continue to offer Call of Duty on PC gaming platform Steam simultaneously to Xbox after the deal closes. The Fly notes that Microsoft has reportedly made similar 10-year commitments to Sony (SONY) to have "Call of Duty" remain on PlayStation. Reference Link

11:37 EST Citi sees Q4 trading revenue growth about 10% - Says credit costs in Q4 likely to be $1.7B-$1.9B. Says credit costs continuing to normalize in Q4. Sees Q4 investment banking revenue likely dropping 60%. Says U.S. recession likely in 2H23. Says in recession in Europe already. Says normalization of credit is happening, though at levels well below the pre-COVID level. Guidance taken from Goldman Sachs U.S. Financial Services conference.

10:41 EST GE Grid Solutions, LineVision parter to deliver dynamic system rating platform - GE Grid Solutions, a GE Renewable Energy business, and LineVision have formed a partnership to deliver the world's first integrated suite of Grid Enhancing Technologies, GETs, providing utilities with an end-to-end Dynamic System Rating, DSR. GE and LineVision will combine Dynamic Line Ratings, Dynamic Power Rating, and Optimal Power Flow Controllers to increase transmission capacity while ensuring grid reliability. "Our utility clients know that increased renewable integration and electrification requires a flexible and dynamic grid," said Claudia Cosoreanu, CTO of GE Grid Automation, Grid Solutions. "Dynamic System Rating will change how utility operators optimize the grid and enable them to integrate more renewables using the same infrastructure. This will reduce the amount of investment needed to reach decarbonization goals and keep the electricity costs to affordable levels for everyone.

10:18 EST Paramount CEO says view of 2023 as peak streaming investment year hasn't changed - Paramount CEO Bob Bakish is being interviewed on CNBC.

10:00 EST United Natural Foods falls -12.0% - United Natural Foods is down -12.0%, or -$5.45 to $40.13.

10:00 EST Carvana falls -33.1% - Carvana is down -33.1%, or -$2.22 to $4.49.

10:00 EST China Eastern Airlines rises 8.8% - China Eastern Airlines is up 8.8%, or $1.69 to $20.77.

10:00 EST Edoc Acquisition Corp trading resumes

09:47 EST Zuora falls -9.7% - Zuora is down -9.7%, or -70c to $6.51.

09:47 EST Carvana falls -38.3% - Carvana is down -38.3%, or -$2.57 to $4.14.

09:47 EST Super Group rises 8.2% - Super Group is up 8.2%, or 24c to $3.16.

09:45 EST Jehoshaphat Research short Progyny, says company 'actually unprofitable' - Jehoshaphat Research said in a recently published report that it is short Progyny as it believes the latter is "deceiving the investor community via its financial reporting practices." "These practices rely on complex accounting that PGNY appears to have been exploiting for years. We believe that PGNY recently has taken its aggression to a brazen level by secretively changing important accounting policies that materially inflate profits. We calculate that PGNY is actually unprofitable, but masks this problem with accounting games," the report reads. Reference Link

09:41 EST Progyny down 7% after short seller publishes critical report - Shares of Progyny are down $2.07, or about 7%, to $29.91 after Jehoshaphat Research published a report and said it is shorting the stock.

09:39 EST Hershey announces first bilingual manufacturing facility - The Hershey Company announced its first bilingual manufacturing facility. Through the launch of the company's 'Say Hola' initiative, the Hershey plant in Hazleton, Pennsylvania now seamlessly integrates both Spanish and English-speaking employees. The transformation evolves Hershey's employee experience and ensures a work environment that's accessible and equitable. In place for nearly one year, the program has enabled hiring of a more experienced workforce, improved retention and reduced recruitment costs. 'Say Hola' further advances Hershey's commitments to its communities while underscoring enterprise-wide DEI priorities, career development programs and enhanced care systems and rewards for employees.

09:35 EST Carvana trading halted, volatility trading pause

09:27 EST WidePoint says Soft-ex launched in Ingram Micro Cloud Marketplace - WidePoint Corporation announced that its subsidiary Soft-ex Communications has been formally launched in the Ingram Micro Cloud Marketplace for its innovative Voice Analytics solution which helps drive Microsoft Teams usage and adoption.

09:26 EST Performance Shipping regains compliance with Nasdaq minimum bid price rule - Performance Shipping announced that the Nasdaq Stock Market has confirmed that the Company has regained compliance with Nasdaq's minimum bid price requirements for continued listing on the Nasdaq Capital Market. The letter noted that, as a result of the closing bid price of the Company's common shares having been at $1.00 per share or greater for at least ten consecutive business days, from November 15, 2022 through November 29, 2022, the Company has regained compliance with Nasdaq's Listing Rule 5550(a)(2), and the matter is now closed.

09:25 EST Edoc Acquisition Corp trading halted, news pending

09:18 EST Armstrong World Industries, Spacekit partner to offer acoustical wall art - Armstrong World Industries announced a partnership with Spacekit, allowing Spacekit to offer its unique modular, acoustical wall art for sale on Armstrong's direct-to-customer, digital sales platform, KanopibyArmstrong.com. Spacekit products broaden Kanopi's assortment of high design, customizable solutions with acoustic benefits for office, retail, dining, hospitality and other commercial settings.

09:11 EST Qualigen announces pre-IND feedback from FDA on QN-302 - Qualigen Therapeutics announces that it has received feedback from the FDA following a pre-Investigational New Drug interaction regarding the development pathway to a Phase 1 clinical trial of QN-302 for the treatment of G4-targeted advanced solid tumors. The purpose of the pre-IND interaction was to inform the proposed content of the Company's IND application and request guidance from the Division on specific questions prior to submission of the IND application. The FDA's response provides Qualigen with clear guidance for formally submitting an IND application for QN-302 after accounting for the agency's comments and suggestions. "We are pleased to have received the feedback from the FDA that informs our plans for the proposed Phase 1 study intended for patients with advanced solid tumors as well as the proposed content of the initial IND application. We remain on track to submit the IND application around the first half of 2023," said Tariq Arshad, M.D., M.B.A., Qualigen's Chief Medical Officer.

09:10 EST PLBY Group amends credit agreement to enhance covenant flexibility - PLBY Group announced today that it amended its senior secured credit agreement to, among other things, give the Company the ability to waive applicable net leverage ratio covenants up through the second quarter of 2024 in connection with certain prepayments of the term loan under the credit agreement.

09:04 EST United Maritime announces ex-dividend date for special cash dividend - United Maritime announced that January 11, 2023 has been set by NASDAQ as the ex-dividend date for the special cash dividend announced on November 29, 2022. As previously announced, the Company's board of directors declared a special cash dividend of $1.00 per share payable on January 10, 2023 to shareholders of record as of the close of trading on December 12, 2022. As a result of "due bill" trading procedures established by NASDAQ, any purchasers of United's common shares in the market through the payment date for the special dividend of January 10, 2023 will be entitled to receive the special dividend, and holders of United's common shares will need to hold their shares through and including the payment date in order to receive the special dividend.

09:03 EST Tecogen appoints Albertine to board of directors - Tecogen (TGEN) announces the appointment of Dr. John Albertine to the Board of Directors. Dr. Albertine has served on the Board of numerous public companies including Fruit of the Loom, Thermo Electron Corporation (TMO) American Precision Industries, Intersections Inc, and DynaTech Corporation.

09:02 EST Digital Brands e-commerce revenue up 436% during Black Friday and Cyber Monday - Digital Brands Group announced that its multi-brand website experienced a 436% increase in e-commerce revenue during its Black Friday/Cyber Monday promo period versus the same period a year ago. The site offers products across DBG's women's brands.

09:02 EST Shineco subsidiary granted USPTO patent, FDA approval of in-situ sample device - Shineco announced that its controlling affiliate, Changzhou Biowin Pharmaceutical, has been granted a patent by the United States Patent and Trademark Office protecting its in-situ fecal specimen sampling device for the use of stool test sample collection, and the marketing approval of the product by the Food and Drug Administration. This product provides a massager-like fingertip swab, a collection tube and a lid with unidirectional sampling inlet. It is a leading stool sample collection device on the market that can be used for self-collection while defecation and does not need a container or plastic bag for this process. After collection, the laboratory staff can finish all of the testing procedures without opening the sample tube. "We are extremely pleased with the grant of a U.S. patent and the marketing approval from FDA for our Easy-to-Use disposable stool test sample collector, which gives us strong support to optimize the stool sample collection in clinical stool test," said Dr. Marvin Liu, the Chairman of CBP, in a press release, and he also commented, "The stool test is a very common clinical lab examination and requires the collection of stool sample from the patient, but the current collection method is not very convenient and requires the passing of a stool specimen into a clean, dry container directly or placing a plastic bag inside the bowl using a toilet. This Easy-to-Use disposable stool test sample collector provides a very simple, easy and complete privacy protected tool for stool sample collection. The collection procedure can be done while defecation on squatting or sitting or can be done after defecation. This not only prevents samples from contamination, but also provides a sanitary measure for laboratory staff to work on the stool sample."

08:47 EST ADMA Biologics prices public offering for $60M of common stock - ADMA Biologics priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on December 9, 2022, subject to the satisfaction of customary closing conditions. The Company has also granted the underwriters a 30-day option to purchase up to 3,146,853 additional shares of common stock at the public offering price before deducting underwriting discounts and commissions. ADMA intends to use the net proceeds from this offering to accelerate commercialization and production activities, complete plasma center buildout and obtain FDA approvals, to conclude post FDA marketing approval research and development projects, and for working capital, capital expenditures and for general corporate purposes. Raymond James & Associates, Inc., Cantor Fitzgerald & Co. and Mizuho Securities USA LLC are acting as joint book-running managers of the offering.

08:47 EST Grid Dynamics introduces pricing, promotion optimization starter kit - Grid Dynamics Holdings announced it is releasing a new Pricing and Promotion Optimization Starter Kit. Developed to leverage Microsoft Azure, the new kit enables customers to create price management pipelines on Azure that leverage historical sales data, product attributes, competitor pricing, and information about various external factors to automatically and intelligently optimize list prices and promotions.

08:46 EST Moleculin Biotech granted FDA Fast Track designation for WP1122 - Moleculin Biotech announced that the U.S. FDA has granted Fast Track designation of WP1122 for the treatment of Glioblastoma Multiforme. The FDA's Fast Track designation is intended to potentially facilitate the development and expedite the review of novel therapies to treat serious conditions for which there is unmet medical need. With the Fast Track designation, Moleculin is potentially eligible for more frequent regulatory meetings and communications with the FDA.

08:44 EST X4 Pharmaceuticals prices $65M public offering - X4 Pharmaceuticals announced the pricing of its previously announced underwritten public offering of 52,300,000 shares of its common stock and, in lieu of common stock, pre-funded warrants to purchase 6,800,000 shares of its common stock, and accompanying Class C warrants to purchase 29,550,000 shares of its common stock at an exercise price of $1.50 per share of common stock at a price to the public of $1.10 per share and accompanying Class C warrant. X4 has also granted the underwriters a 30-day option to purchase up to an additional 8,865,000 shares of its common stock and/or Class C warrants to purchase up to an additional 4,432,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. X4's gross proceeds from this offering are expected to be approximately $65.0 million before deducting underwriting discounts and estimated offering expenses and any proceeds from the exercise of the warrants to be issued in the offering. All of the securities in the offering are being sold by X4. The offering is expected to close on or about December 9, 2022, subject to customary closing conditions. Piper Sandler, Stifel and Cantor are acting as joint book-running managers for the offering. H.C. Wainwright & Co. and Brookline Capital Markets are acting as financial advisors for the offering.

08:40 EST Ageagle Aerial Systems appoints Kelly Anderson to board of directors - AgEagle Aerial Systems announced the appointment of Kelly Anderson, CPA as a new independent member of AgEagle's Board of Directors, effective today, December 5, 2022. Anderson will also serve as Chairperson of the Audit Committee and as a member of both the Compensation Committee and Nominating and Corporate Governance Committee of the Board, effective December 5, 2022. Anderson currently serves as CEO of CXO Executive Solutions, a specialized executive talent solutions company she founded in 2020.

08:39 EST Globalstar in pact with Wiagro to supply IoT transmitters for agriculture - Globalstar announced a commercial agreement with Wiagro, an Agtech start-up from Argentina. Globalstar is supplying Wiagro with 2,500 ST100 satellite modem transmitters for their Smart Silobag , which allows for the remote monitoring of grain conditions stored in silo bags. The partnership is effective immediately with completion of deployment anticipated through the end of 2024. Juan Porras, Globalstar Latin America General Manager, stated, "Agriculture is quickly adopting IoT technology in Latin America and Globalstar is well equipped to provide developer solutions that enable reliable satellite connectivity for tracking and monitoring. We have already established a presence in Brazil, and we are now expanding into Argentina with our partner, Wiagro."

08:36 EST AstraZeneca reports updated results from DESTINY-Breast03 Phase 3 trial - Updated results from the DESTINY-Breast03 Phase III trial showed that Enhertu demonstrated a "statistically significant and clinically meaningful" improvement in overall survival, or OS, compared to trastuzumab emtansine in patients with HER2-positive unresectable and/or metastatic breast cancer previously treated with trastuzumab and a taxane, AstraZeneca reported. These results and primary results from the DESTINY-Breast02 Phase III trial will be presented today at the 2022 San Antonio Breast Cancer Symposium, or SABCS, with the updated results from DESTINY-Breast03 simultaneously published in The Lancet. Enhertu is a specifically engineered HER2-directed antibody drug conjugate being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. In the key secondary endpoint analysis of OS for DESTINY-Breast03, Enhertu demonstrated a 36% reduction in risk of death versus T-DM1. In both treatment arms, median OS was not yet reached after a median duration of follow-up of 28.4 months for Enhertu and 26.5 months for T-DM1. An estimated 77.4% of patients were alive in the Enhertu arm at two years compared to 69.9% of patients treated with T-DM1. The observed survival benefit was consistent across all analyzed subgroups, including patients with or without baseline brain metastases, with or without baseline visceral disease, those who were hormone receptor (HR)-positive or HR-negative, and regardless of prior pertuzumab or lines of systemic therapy.

08:35 EST Luna secures $3M Northrop Grumman order for OBR 6200 reflectometer - Luna Innovations (LUNA) announced that it has extended its existing relationship with Northrop Grumman (NOC) by securing a new multi-year, multi-million-dollar agreement. The agreement includes an initial receipt of an over $3M incremental, multi-unit purchase order for the OBR 6200 portable backscatter reflectometer. "We are excited to continue our strong relationship with Northrop Grumman, and we look forward to continuing our work with them providing critical testing and monitoring technology for the aerospace and defense industry," said Scott Graeff, President and CEO of Luna Innovations. "Luna has a long history of working in close collaboration with our partners to provide the products that meet and exceed their needs. We are honored that companies like Northrop Grumman and Lockheed Martin recognize the quality of our technology." The order is structured as a multi-year agreement with Northrop Grumman, one of the world's largest aerospace and defense technology companies, who oversees procurement and distribution, along with Lockheed Martin, of sustainment equipment for the F-35 aircraft. As Luna has reported previously, the OBR 6200 instrument is included with the sustainment equipment when F-35s are deployed globally.

08:34 EST One Stop Systems wins multi-million-dollar AI transportable program - One Stop Systems has won a multi-year, multi-million-dollar program with a Fortune 50 cellular provider to supply OSS transportable compute and storage hardware for a mobile 5G AI application. The deployment will involve installing OSS SDS rugged servers in service vehicles operating in more than 100 cities nationwide. The vehicles will use onboard 5G antennas to gather and characterize data real-time in the field, and then transport the data back to a service hub where it is uploaded to the cloud and combined with other data sets. "This leading 5G cellular provider chose OSS because of our technology leadership and long history of delivering rugged compute and storage solutions for transportable applications, particularly those involving high-speed data recording," stated OSS CEO, David Raun. "We anticipate a long-term relationship developing under this commercial program win and it leading to other opportunities with this marquee customer." OSS expects initial deliveries of the mobile 5G AI system to begin before the end of this year, with deployments continuing through 2026.

08:33 EST Evoke Pharma announces USPTO granted new patent covering GIMOTI - Evoke Pharma announced that the United States Patent and Trademark Office, USPTO, issued US patent No. 11,517,545 under the title "Treatment of Moderate and Severe Gastroparesis." This patent expires in 2038 and covers the methods for treating moderate-to-severe gastroparesis with metoclopramide via an intranasal route of administration. The patent expands Evoke's patent portfolio, which includes U.S. Food and Drug Administration Orange Book-listed patents and other patents in the EU, Japan, Canada, and Mexico. "The grant of this patent validates the efficacy signals we observed in our Phase 3 trial results from utilizing nasal metoclopramide to treat patients suffering from moderate-to-severe gastroparesis," commented Matt D'Onofrio, MBA, Chief Business Officer of Evoke Pharma. "We are thrilled to add this new patent to our IP estate, primarily focused on ensuring the long-term availability of our novel product, GIMOTI, to help patients and healthcare providers in need of a revolutionary solution to treat diabetic gastroparesis symptoms," he added.

08:32 EST Minim expands e-commerce footprint with OfficeDepot.com - Minim (MINM) announces the launch of eight Motorola home networking products on OfficeDepot.com, a wholly-owned subsidiary of The ODP Corporation (ODP). This new partnership will expand the WiFi 6 Motorola Mesh portfolio to one of the largest e-commerce platforms in the office supply segment. "Minim is delighted to work with the Office Depot team," said Jeffrey Rodning, Vice President of Retail Sales at Minim. "We're excited to provide a new cohort of customers with our dependable range of Motorola networking devices. This relationship takes us one step further in our mission to help people do more and live better with connectivity."

08:31 EST Amarin announces VAZKEPA receives regulatory approval in Switzerland - Amarin Corporation announced that Switzerland's Swissmedic has granted approval to VAZKEPA. Swissmedic approved VAZKEPA to reduce risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides and established cardiovascular disease, or diabetes and at least one other cardiovascular risk factor. In parallel with the regulatory submission, Amarin had already initiated the process for obtaining national pricing and reimbursement in Switzerland, which is expected to conclude in the course of 2023. "This latest regulatory approval of VAZKEPA in Switzerland not only underscores the urgent need for proven therapies to help address residual cardiovascular risk for patients globally, it is also another example of an international health authority recognizing the value of our robust scientific evidence and innovative treatment to meet this need," said Steven Ketchum, PhD., President, Research & Development and Chief Scientific Officer, Amarin. The approval in Switzerland marks the sixth approval for the VASCEPA/VAZKEPA franchise within 2022.

08:29 EST NLS Pharmaceutics receives Nasdaq minimum bid price notification - NLS Pharmaceutics announced that it had received a written notice from The Nasdaq Stock Market LLC, indicating that the Company was not in compliance with the minimum bid price requirement for continued listing set forth in Listing Rule 5550(a)(2), which requires listed companies to maintain a minimum bid price of $1.00 per share. Under Nasdaq Listing Rule 5810(c)(3)(A), the Company had been granted a period of 180 calendar days to regain compliance with the minimum bid price requirement. Upon the expiration of that grace period, on December 6, 2022, NLS received an additional written notice from the Nasdaq Staff that the bid price issue provides a separate basis for delisting of the Company's common shares. Accordingly, the Company has been afforded an opportunity to provide a further update to the Nasdaq Hearings Panel in connection with its ongoing listing review. In that regard, at its prior hearing before the Panel, the Company provided its plan for regaining compliance with the bid price requirement, notwithstanding the fact that the Company remained in a grace period at the time of the hearing. The Company's plan for addressing the bid price issue that was presented at the hearing has not changed and the Company intends to provide a further update to the Panel as permitted. As previously announced on November 14, 2022, following the hearing before the Panel, on November 11, 2022, the Panel granted the Company an extension through February 28, 2023, subject to certain milestones, to regain compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. The Panel considered the Company's plan for addressing the bid price issue in rendering that decision.

08:27 EST Ensysce Biosciences announces pricing of $4.1M public offering - Ensysce Biosciences announced the pricing of an underwritten public offering of 2,900,000 shares of its common stock and warrants to purchase up to an aggregate of 5,800,000 shares of common stock at a combined effective public offering price of $1.40 per share of common stock and accompanying warrants. Each warrant is exercisable immediately at an exercise price of $1.40 per share and will expire five years following the date of issuance. The Company expects to receive aggregate gross proceeds of approximately $4.1 million from the offering. The offering is expected to close on or about December 9, 2022, subject to satisfaction of customary closing conditions. Lake Street Capital Markets, LLC is acting as the sole underwriter for the offering. The Company has also granted the underwriter a 45-day option to purchase up to an additional 342,000 shares of common stock and/or warrants to purchase up to an additional 870,000 shares of common stock at the public offering price, less the underwriting discounts and commission, to cover over-allotments, if any. 20% of the gross proceeds of the offering will be used to repay a portion of the Company's outstanding convertible notes. The Company intends to use the remaining net proceeds from the offering for the further clinical development of its product candidates and for working capital and other general corporate purposes.

08:26 EST Triumph Bancorp announces preliminary results of tender offer - Triumph Financial announced the preliminary results of its modified "Dutch auction" tender offer to purchase up to $100 million of its common stock for cash at a price per share not less than $51.00 and not greater than $58.00, which expired at 12:00 midnight, New York City time, at the end of the day on December 6, 2022. Based on the preliminary count by Equiniti Trust Company, the depositary for the tender offer, a total of 408,615 shares of Triumph's common stock, $0.01 par value per share, were properly tendered and not properly withdrawn at or below the purchase price of $58.00 per share, including 4,236 shares that were tendered by notice of guaranteed delivery. In accordance with the terms and conditions of the tender offer, and based on the preliminary count by the depositary, the Company expects to acquire 408,615 shares of its common stock, at a price of $58.00 per share, for an aggregate cost of approximately $23,699,670, excluding fees and expenses relating to the tender offer. The 408,615 shares that the Company expects to accept for purchase represent approximately 1.67% of the Company's shares outstanding as of December 5, 2022. As the Company expects to accept for purchase all the shares that were properly tendered at a price at or below $58.00 and not properly withdrawn, the Company expects there to be no proration factor.

08:21 EST Generac acquires equity stake in WATT Fuel Cell - Generac Power Systems announced a minority equity investment in WATT Fuel Cell Corp, WATT, a leading developer and manufacturer of low emissions Solid Oxide Fuel Cell, SOFC, stacks and systems. Generac and WATT plan to collaborate on the design and development of low-emission solutions supporting the resiliency needs of Generac's customers. The companies will combine WATT's highly reliable, low-emission technology with Generac's clean energy portfolio of products, which includes microinverters and battery storage system solutions. "Generac is the perfect partner to assist us in accelerating the development and commercialization of our fuel cell power generation technology," said Caine Finnerty, president and co-founder of WATT. "Generac's strong expertise in residential home resiliency and clean energy products will provide access to a national base of installation partners, thereby accelerating the path to a low carbon future. We look forward to all the incredible opportunities this partnership will provide."

08:20 EST BYND Cannasoft advances stages of expanding its EZ-G device's applications - BYND Cannasoft Enterprises announced it is in the advanced stages of expanding its EZ-G device's applications into the leisure field of sex toys. In addition to potentially treating annoying phenomena in the female reproductive system, the EZ-G device includes technological advancements as a sex toy with a more realistic experience. "Since BYND Cannasoft acquired the rights to the EZ-G device two months ago, we have found several potential applications after filing our application under the Patent Cooperation Treaty," said Yftah Ben Yaackov, CEO and Director of BYND Cannasoft. He continued, "Our EZ-G device could not only treat annoying phenomena in the female reproductive system, it could also present us with an opportunity to enter the growing adult novelty toy business and potentially develop our recently announced double-faceted condom. We believe this could be a tremendous opportunity since the adult novelty toy market is fragmented and many vendors are focusing on the R&D of new products with multifunctional benefits using natural ingredients to compete in the market."

08:19 EST Star Equity nominates directors to Firsthand Technology board - Star Equity Fund is an investment fund seeking to unlock shareholder value and improve corporate governance at its portfolio companies. As a 5.1% shareholder of Firsthand Technology Value Fund, they have nominated two candidates for election to the Company's board of directors at the Company's 2023 Annual Meeting of Shareholders. "The SVVC shareholders have long suffered value destruction during the tenure of the Company's incumbent Board of directors; thus, we have concluded that significant change to the Board is necessary to create value for all shareholders," the company said. Because of the entrenchment of the incumbent Board through the Company's classified Board structure, SVVC shareholders are only able to run a minority slate for election at the 2023 Annual Meeting. Star Equity has nominated two highly qualified candidates for election to the Board at the 2023 Annual Meeting, Hannah Bible, and Robert Pearse

08:16 EST Beam shipped, deployed record number of EV ARC charging systems in November - Beam Global announced that it shipped and deployed a record number of sustainable EV ARC EV charging systems in the month of November, higher than any other month in company history. Beam Global is expanding its fleet of deployment personnel and vehicles, including its new ARC Mobility trailer, a specialized hydraulic transportation solution which enables the rapid deployment or relocation of off-grid EV ARC systems by a single operator. "Sales of our products are at all-time record highs and our ramp-up in production and operational capacity is well under way," said Beam Global CEO Desmond Wheatley. "The accelerating urgency for EV charging infrastructure combined with the need for robust, off-grid solutions is driving significant growth in demand for our products, and our operations teams are taking the necessary steps to execute on this increasing demand. We have a great deal of operating leverage and the ability to continue to expand our output dramatically without an equivalent level of further investment."

08:14 EST IntelGenx, UPEI collaborate to evaluate performance of VetaFilm in dogs, cats - IntelGenx announced a research collaboration with the University of Prince Edward Island, UPEI, to assess palatability, owner-perceived acceptability, and ease of administration of IntelGenx's VetaFilm platform in healthy dogs and cats. Through a series of studies, the collaboration will evaluate: the acceptance rate of various VetaFilm placebo formulations in dogs and cats at first exposure; preference between flavours of VetaFilm placebo formulations in dogs and cats changes in acceptance rates over longer periods; and, owner perception of ease of administration, acceptance and other behaviors associated with VetaFilm placebo formulations. "We are thrilled to combine our efforts with one of North America's leading veterinary universities," said Dr. Horst G. Zerbe, CEO of IntelGenx. "There are a number of clinical advantages with administering drugs to pets via our VetaFilm platform. Studies have demonstrated that, when administering capsules and tablets to dogs and cats, there can be a delay in reaching the stomach. But more importantly, certain medication can cause significant mucosal damage when allowed to sit in the esophagus for a prolonged period, which is often the case when 'dry-pilling'. Finally, from a pharmacokinetic standpoint, buccal absorption may decrease the overall amount of drug required as first pass metabolism would be largely avoided. All that said, we believe offering VetaFil products that address subjective preferences of both pets and their owners and will be key to the platform's commercial success."

08:12 EST Sysco announces launch of 10th CDL driver training facility - Sysco Corporation announced the recent launch of its 10th professional truck driver training facility since March 2022. The leading global foodservice distribution company now operates Commercial Driver's License training facilities at Sysco sites throughout the United States.

08:11 EST Otonomo Technologies partners with Renault Group for fleet modernization - Otonomo Technologies announced a multi-year partnership with global automobile manufacturer Renault Group. Under the agreement, in partnership with Renault Group, Otonomo will provide to its fleet customers easier and cost-effective access to rich, actionable vehicle data insights across multiple vehicle brands. Otonomo is one of the first major multi-brand software platforms to partner with Renault Group that does not require aftermarket hardware to be installed to access fleet vehicle data. "Working with Renault Group is another important milestone that will drive future fleet business models, strengthen our fleet offering and continue innovating in the automotive and mobility sectors leveraging their extensive connected vehicle data," said Ben Volkow, CEO and co-founder at Otonomo. "This partnership not only enables Renault Group to expand its portfolio to serve new multi-brand fleet owners, but also enriches our Smart Mobility Data Platform, which helps our customers focus on value creation instead of data pipelining and connectivity engineering."

08:10 EST Robinhood reports November MAUs 12.5M - Robinhood Markets reported selected monthly operating data for November 2022: Net Cumulative Funded Accounts at the end of November were 23.0 million, up approximately 40 thousand from October 2022. Monthly Active Users, MAU, at the end of November were 12.5 million, unchanged with the end of October 2022. Assets Under Custody at the end of November were $70.2 billion, unchanged with the end of October 2022. Net Deposits were $1.7 billion in November, translating to a 28% annualized growth rate relative to October 2022 AUC. Over the last twelve months, Net Deposits were $18.9 billion, translating to an annual growth rate of 18% relative to November 2021 AUC. Notional Trading Volumes - which are the primary driver of transaction revenues - were higher in November for options and crypto from October 2022, and lower for equities. Equities were $44.7 billion, Option contracts were 81.8 million, and Cryptocurrencies were $5.7 billion. Margin Balances at the end of November were $3.5 billion, down $0.3 billion from the end of October 2022. Cash Sweep Balances at the end of November were $5.0 billion, up $1.2 billion from the end of October 2022.

08:09 EST Brown-Forman sees FY23 capital expenditures $190M-$210M - Sees FY23 effective tax rate 22%-23%. Sees high-single digit organic operating income growth in FY23. The company said, "The company anticipates stronger growth in fiscal 2023 despite global macroeconomic and geopolitical uncertainties."

08:08 EST Vor Bio jumps 13% to $4.85 after pricing stock offering at last night's close

08:07 EST VYNE Therapeutics announces first patent granted for BET inhibtor platform - VYNE Therapeutics announced that GB Patent No. 2597228 entitled "Compounds Comprising N-Methyl-2-Pyridone, And Pharmaceutically Acceptable Salts" has been granted by the United Kingdom's Intellectual Property Office. This granted patent covers the compound in VYNE's VYN201 program and has a 20-year term that will expire in April 2040. This newly issued patent is derived from The University of Dundee's PCT application No. WO 2020/216779, which was filed nationally in multiple jurisdictions, and is exclusively licensed to Tay Therapeutics Limited and sublicensed to VYNE. This patent is the first of the national filed applications to be granted in connection with VYNE's bromodomain and extra-terminal domain inhibitor program.

08:05 EST Cognizant to acquire Utegration, terms not disclosed - Cognizant announced it has agreed to acquire Houston-based Utegration LLC, a full-service consulting and solutions provider specializing in SAPtechnology and SAP-certified products for the energy and utilities sectors. Cognizant will gain approximately 350 employees in North America and India upon the close of the acquisition. The acquisition is expected to close by year-end 2022, subject to satisfaction of closing conditions. Financial details were not disclosed.

08:03 EST DINAMO phase III clinical trial met primary endpoint - The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c with Jardiance compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes. When Jardiance was added to other baseline treatments HbA1c was reduced by 0.84% compared with placebo at week 26. The results were presented at the International Diabetes Federation, or IDF, World Diabetes congress 2022, Boehringer Ingelheim and Eli Lilly and Company announced. The DINAMO,DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents, trial included youth aged 10-17 years with type 2 diabetes and HbA1c greater than or equal to6.5% and less than or equal to10.5%. Participants were randomly assigned treatment with Jardiance, Tradjenta or placebo once daily. All participants were treated with diet and exercise plus, when appropriate, metformin and/or insulin.

07:59 EST Welltower drops12% to $68.20 after Hindenburg discloses short position

07:52 EST A2Z Smart Technologies announces IR services agreement with Hanover - A2Z Smart Technologies entered into an investor relations services agreement with Hanover International. Under the terms of the engagement, the Company will pay Hanover a fee of $4,000 per month for an initial twelve-month term. The Agreement may also be terminated, after the initial 90-day period, at any time without charge by either party by giving 30 days' notice. In addition, Hanover shall be granted 100,000 stock options to purchase common shares in the capital of the Company at a price per Share that is equal to $1.50. The Options shall vest quarterly over a 12-month period. All vested Options shall be eligible for exercise for a period ending five years from the date of the grant. To the knowledge of the Company, Hanover does not own or control, directly or indirectly, any securities of the Company. The IR Agreement is subject to the approval of the TSX.

07:49 EST Avrobio announces new Gaucher Disease data, outlines development plans - AVROBIO announced new interim pharmacokinetic, pharmacodynamic and clinical efficacy data, showing stabilization or reversal of multiple clinically relevant measures in five patients with Gaucher disease after they received a single dose of AVR-RD-02, an investigational hematopoietic stem cell gene therapy. In addition, following positive discussions with regulators, AVROBIO plans to initiate a global, registrational Phase 2/ 3 clinical trial in Gaucher disease type 3 in the second half of 2023..."We are thrilled to share new, compelling data from patients impacted across the spectrum of Gaucher disease, the most common lysosomal disorder. This includes what we believe to be transformational data from the first pediatric GD3 patient treated with an HSC gene therapy, showing complete biochemical correction, which means both enzyme activity and substrate levels have normalized post gene therapy. This pharmacodynamic efficacy equates with improvements in major refractory elements of disease for this patient, something the child has never experienced on current standard of care," said Essra Ridha, M.D., MRCP, FFPM, chief medical officer at AVROBIO. "Following constructive regulatory conversations, including with FDA, we are now focused on initiating a randomized controlled, Phase 2/3 clinical trial for GD3 next year, the first such trial for a gene therapy, to further evaluate the benefit-risk profile of AVR-RD-02 in a clinical trial setting." AVROBIO believes its plato gene therapy platform is late stage-trial ready, with no major CMC changes anticipated

07:43 EST Emerita Resources announces additional assay results from La Romanera Deposit - Emerita Resources announces additional assay results from the 2022 delineation drilling at the La Romanera Deposit at its wholly owned Iberian Belt West project. The Company is highly encouraged by the results to date. Joaquin Merino, P.Geo., President of Emerita, notes: "Given the increasing dimensions of the lenses in longitudinal section and plan, we anticipate an increase in tonnes relative to the historical calculation. Keep in mind, not all of the massive sulphide will be above the cut off grade so no direct comparison can be made until we complete the drill program and model the deposit. However, drills are now targeting a very important area of the deposit that hosts some of the thickest and highest grade sections based on the historical drilling and much of this area was not assayed for gold. Presently, there are approximately 60 additional drill holes between the core shack and the assay labs with results pending."

07:40 EST Motional and Uber to launch public autonomous robotaxi service in Las Vegas - Motional and Uber "announced the launch of their public robotaxi service in Las Vegas, NV. For the first time ever, Uber customers are able to hail an autonomous ride using Motional's all-electric Hyundai IONIQ 5-based robotaxis. Motional and Uber are launching with vehicle operators now to lay the groundwork for a fully driverless commercial service, with the goal of launching the driverless service to the public in 2023. This service is the first in Motional and Uber's 10-year commercial partnership that will see Motional's Level 4 autonomous vehicles deployed for ride-hail and deliveries on the Uber network in major cities across the U.S. The public robotaxi service will first launch in Las Vegas before expanding at a later date to Los Angeles, CA. The Las Vegas pilot arrives just a few months after Motional and Uber finalized the multi-year partnership, demonstrating that both companies are committed to entering new markets and introducing autonomous technology at scale to millions of Uber customers - all while making meaningful progress on leading the industry to zero emissions." Reference Link

07:38 EST Cytokinetics initiates Phase 1 clinical study of CK-3828136 - Cytokinetics (CYTK)announced that the first participants have been dosed in a Phase 1 randomized, double-blind, placebo-controlled, single and multiple ascending dose clinical study of CK-3828136, formerly known as AMG 594. CK-136 is a cardiac troponin activator, discovered under a previous joint research program with Amgen (AMGN), in development for the potential treatment of patients with heart failure with reduced ejection fraction and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility. "This Phase 1 study builds on previous first-in-human data for CK-136 by assessing a wider range of doses to determine a dose range associated with improvements in left ventricular systolic function, in addition to safety and tolerability," said Fady I. Malik, M.D., Ph.D., Cytokinetics' Executive Vice President of Research & Development. "The advancement of CK-136 extends our cardiovascular franchise, as it may provide differentiated effects for the potential treatment of certain forms of heart failure and conditions associated with reduced cardiac contractility."

07:37 EST Aehr Test Systems receives inital production order for FOX-XP multi-wafer test - Aehr Test Systems announced it has received an initial production order from its new major silicon carbide semiconductor supplier customer for a FOX-XP multi-wafer test and burn-in system configured with Aehr's new fully integrated and automated WaferPak Aligner. The FOX-XP system is configured with Bipolar Voltage Channel Module and Very High Voltage Channel Module options which enable new advanced test and burn-in capabilities for silicon carbide power semiconductors using Aehr's proprietary WaferPak full wafer Contactors. This customer serves several significant markets including the electric vehicle industry as well as other industrial applications. This production system order is a follow-on to an order announced last quarter for a FOX-NP system that has already been installed at the customer's site. Shipments of the FOX-XP system with the new integrated and automated WaferPak Aligner are expected to begin in Aehr's fiscal fourth quarter that begins March 1, 2023.

07:36 EST Draganfly launch new flight facility for land mine, anomaly detection protocols - Draganfly announces the launch of the Draganfly UAS A.I.R. Space, flight facility dedicated to the advancement of UAS program Adoption, Innovation & Research. The Draganfly UAS A.I.R. Space provides a control site for the design, validation and optimization of standard operating procedures, sensor selection and data collection techniques. In partnership with Coldchain Delivery Systems, testing at the site is in currently focused on protocol for anomaly detection to aid in the identification of mines and unexploded ordinance as well as UAV Delivery for emergency response and humanitarian aid. Located in Spring Branch, Texas, the flight facility will enable remote sensor testing from drones for various mines and other unexploded ordinances on and below the surface. "The ability to safely test mapping, equipment, technology, and potential use cases in a controlled non-threatening environment will enable Draganfly to continue its innovation and research in relation to mine detection and a variety of other UAV programs," said Cameron Chell, President and CEO of Draganfly. "We are excited about this one of kind flight facility that we have launched with Coldchain Delivery Systems and the amazing results that will benefit not only our partners and customers but the industry as a whole."

07:34 EST Versus Systems announces pricing of $2.1M public offering - Versus Systems announced the pricing of its public offering of 2,100,000 units for gross proceeds of approximately $2.1M, before deducting placement agent fees and other offering expenses payable by Versus. Each unit consists of either one common share or one pre-funded warrant to purchase one common share and two warrants to purchase one common share each, at a public offering price of $1.00 per unit. The warrants will have an exercise price of $1.10 per share, are exercisable immediately upon issuance, and will expire five years following the date of issuance. All of the shares, pre-funded warrants and warrants included in this offering are being sold by Versus. The offering is expected to close on December 9, 2022, subject to customary closing conditions. The Company intends to use the net proceeds from the offering for working capital and general corporate purposes, including marketing and sales expenses, the costs and expenses of our continuing development of our engagement and rewards platform and salaries and wages. Roth Capital Partners is acting as the exclusive placement agent for this offering.

07:33 EST Titan Medical suspends special meeting of shareholders - Titan Medical announced that in view of the commencement of the strategic review process announced on November 30, 2022, the special meeting of its shareholders scheduled for January 12, 2023 will be suspended and, if appropriate and necessary, rescheduled to a future date. If rescheduled to a future date, the business of the meeting may include, to the extent required by corporate or securities law and as determined by the Board of Directors of the company, the approval of a potential transaction should one result from the strategic review process announced on November 30, 2022 or, if appropriate, the approval of a consolidation of the company's common shares. Cary Vance, Titan's President and CEO, commented, "After consultation with our financial and legal advisors, we determined it was in the best interest of the company and its shareholders to suspend the special meeting. This action, in addition to resulting in a cost savings, allows the company to focus its attention on the strategic review process, completing tasks towards an IDE filing with the FDA and fulfilling certain other contractual development and supply obligations."

07:31 EST NexGel approves $500,000 share repurchase program - NEXGEL announces that its Board of Directors has approved a share repurchase program, effective immediately, with authorization to purchase up to $500,000 of the Company's common shares.

07:14 EST Axsome Therapeutics presents data on EVOLVE open-label trial of AUVELITY - Axsome Therapeutics announced that treatment with AUVELITY resulted in rapid, substantial, and durable improvements in cognitive and physical functioning in the EVOLVE open-label trial in major depressive disorder. Treatment with AUVELITY also resulted in reduced disability. These new data were presented yesterday at the American College of Neuropsychopharmacology, ACNP, 2022 Annual Meeting being held in Phoenix, Arizona. In the trial, AUVELITY rapidly, durably, and substantially improved symptoms of depression including cognitive and physical functioning, and reduced disability in patients with MDD who had received one or more prior antidepressants. The change in cognitive and physical functioning was assessed using the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire, a patient-rated scale used to measure cognitive and executive dysfunction in mood and anxiety disorders. The mean CPFQ score at baseline was 28.4. Mean improvements from baseline to weeks 1, 2, and 6 in CPFQ scores were -2.0 points, -4.4 points, and -7.5 points, respectively. Improvements on the CPFQ were sustained through month 6 and month 12. Disability was assessed using the Sheehan Disability Scale, a patient-facing questionnaire used to evaluate impairments in the domains of work, social life/leisure, and family life/home responsibility. The mean SDS score at baseline was 17.5. Mean improvements from baseline to weeks 1, 2, and 6 in SDS scores were -2.9 points, -5.0 points, and -8.3 points, respectively. Improvements on the SDS were sustained through month 6 and month 12.

07:12 EST Enthusiast Gaming announces Verizon, Xbox as NFL TNG sponsors - Enthusiast Gaming Holdings announced it has signed a media sponsorship deal with Verizon and Xbox to become co-presenting sponsors for NFL Tuesday Night Gaming Championship Week. Championship Week presented by Verizon and Xbox will run on Tuesday, December 13, 2022. NFL TNG is a first-of-its-kind gaming collaboration launched earlier this year, bringing together NFL players and Legends and top gaming content creators. The program debuted in September and streams weekly on YouTube and Twitter. Through fun, engaging and exclusive content, Enthusiast Gaming will help deliver to the program's Generation Z and Millennial audiences the value of the Xbox Series S console available from Verizon. Verizon and Xbox will be seamlessly integrated into the Championship Week broadcast from product placements to exclusive owned moments, including behind-the-scenes looks, player communications, and more, all supported across Enthusiast Gaming assets, including YouTube video and desktop media and social media amplification on Twitter, TikTok and Instagram.

07:12 EST Replimune Group announces updates on RP2/3 data, development plans - Replimune Group announced an RP2/3 data updates and development plans. RP2/3 Clinical Update and Development Plan: The Company is pursuing a Phase 2 development plan for RP2 and RP3 targeting tumor types in large and underserved markets, including where liver metastases are common, as well as patients with primary liver cancer, and patients with earlier disease where the objective of treatment would be to achieve a cure. This includes the development of RP2/3 in combination with the current standard of care, including immunotherapy, chemotherapy and radiation, and in settings following the current SOC. RP2/3 Data Updates: The Company is today presenting updated data in uveal melanoma patients from the Phase 1 clinical trial evaluating RP2 in combination with nivolumab. Seventeen patients have been treated with RP2 as monotherapy or in combination with nivolumab to date. Four of the 14 patients which are so far evaluable have responded to treatment, including metastatic tumors in the liver and bone. The final three of 17 patients remain on treatment, but currently have insufficient follow-up data to determine response outcome as of the cut-off date. The Company is also presenting data from a Phase 1 clinical trial of RP3 in combination with nivolumab, in patients with soft tissue sarcomas. Five patients have been treated with RP3 combined with nivolumab in patients with multiple soft tissue sarcomas including in leiyomyosacoma, osteosarcoma, chondrosarcoma, and epithelioid sarcomas who have all have failed standard of care. Overall, RP2/3 continues to demonstrate promising early signals that could unlock additional opportunities in hard to treat cancers. RP2/3 Phase 2 Development Plans: Three Phase 2 clinical trials are to be conducted with RP2/3, each initiating in the first half of 2023. Squamous cell carcinoma of the head and neck: A two cohort clinical trial with RP3 will be conducted, with the first cohort of 100 patients with locally advanced disease being randomized to receive either SOC chemotherapy combined with radiation or RP3 combined with chemotherapy and radiation followed by adjuvant nivolumab therapy. The second, signal finding cohort, will enroll 30 patients with recurrent or metastatic SCCHN with low PDL1 levels who will be treated with chemotherapy, nivolumab and RP3. Hepatocellular carcinoma: Two 30 patient signal finding cohorts of patients will be enrolled. The first cohort of patients will enroll 1L patients treated with SOC atezolizumab combined with bevacizumab and RP3, and the second cohort of patients who have progressed on 1L immunotherapy also to be treated with atezolizumab combined with bevacizumab and RP3. Colorectal cancer: Two 30 patient 3L signal finding cohorts of patients will be enrolled. The first cohort will be treated with atezolizumab combined with bevacizumab and RP2 and the second cohort with RP3 combined with atezolizumab and bevacizumab.

07:11 EST Marqeta integrates with Mastercard Track Instant Pay virtual card solution - Marqeta (MQ) announced that it has integrated Mastercard (MA) Track Instant Pay, a next-generation virtual card solution that uses machine learning and straight-through processing to enable instant payment of supplier invoices. With Track Instant Pay, Marqeta customers in the U.S. will be able to immediately authorize a payment to suppliers after invoices are received instead of waiting for invoices to be approved manually, freeing up time to focus on growing their businesses instead of administrative tasks. This payment process empowers Marqeta customers to pay invoices more efficiently and access cost savings by avoiding costly check processing fees.

07:09 EST Palantir renews $443M contract with CDC - Palantir announced that the Centers for Disease Control and Prevention, or CDC, has renewed its work with the company to continue delivering software and digital capabilities to modernize the nation's public health infrastructure. Using the Palantir platform, the agency will be able to employ scalable technology to plan, manage, and respond to future outbreaks and public health incidents. This five year, $443M contract will streamline Palantir's existing programs - including Health and Human Services Protect, Administration for Strategic Preparedness and Response Engage, Tiberius, and DCIPHER - into a singular vehicle. Under this deal, Palantir's technology will support the CDC's "Common Operating Picture", an inter-agency enterprise investment that secures strong collaboration across the federal government, jurisdictional health departments, private sector entities, and other key health partners. By employing Palantir's software, these groups can continue to make advances in broader disease surveillance and outbreak response, supply chain resiliency, and the orchestration of medical countermeasures to public health emergencies.

07:08 EST Bio-Path announces first patient dosed in Phase 1/1b study of BP1001-A - Bio-Path Holdings announced the enrollment and dosing of the first patient in a Phase 1/1b clinical trial of BP1001-A in patients with solid tumors, including ovarian, endometrial, pancreatic and breast cancer. BP1001-A is a modified drug product with the same drug substance as prexigebersen but includes formulation enhancements to produce smaller drug nanoparticles. The goal of this product enhancement is to produce smaller drug nanoparticles that can pass through vasculature pore spaces, thereby enabling release of the drug product into the interior of the tumor to enhance drug effectiveness. The dose escalation portion of the Phase 1/1b clinical trial is planned to be conducted at more than six leading cancer centers in the United States, including The University of Texas MD Anderson Cancer Center, The Mary Crowley Cancer Research Center, and Karmanos Cancer Center. Initially, a total of nine evaluable patients are scheduled to be treated with BP1001-A monotherapy in a standard 3+3 design, with a starting dose of 60 mg/m2. The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days. The Phase 1b portion of the study will commence after successful completion of BP1001-A monotherapy cohorts and will assess the safety and efficacy of BP1001-A in combination with paclitaxel in patients with recurrent ovarian or endometrial tumors.

07:08 EST China Green announces receipt of NYSE late filer cure letter - China Green Agriculture announced that, on December 6, 2022 the Company received a notice letter from the New York Stock Exchange stating that, effective December 6, 2022, the Company will be removed from NYSE's late filers' list to be disseminated to data vendors and will not be posted on the NYSE's Listed Standards Filing Status page on www.nyse.com. The NYSE's letter comes after the Company filed its delayed Quarterly Report on Form 10-Q for the period ended September 30, 2022, thus becoming current on its financial reporting obligations.

07:06 EST Arko Corp. to acquire assets from WTG Fuels for $140.4M - ARKO Corp. announced that subsidiaries of ARKO have agreed to acquire the retail, wholesale and fleet fueling assets of WTG Fuels Holdings, the owner of Uncle's Convenience Stores and GASCARD fleet fueling operations. Founded in 1976, WTG is a leading Texas convenience store operator, with 24 company-operated Uncle's Convenience Stores across western Texas. This acquisition would enhance ARKO's footprint in these attractive markets and bring our fas REWARDS loyalty program and favorable assortment to a broader group of consumers. The transaction also includes three land parcels and nine independent dealer locations. The Company has also agreed to acquire WTG's 57 proprietary GASCARD-branded fleet fueling cardlock sites and 52 private cardlock sites, one of the largest fleet fueling operations in West Texas. ARKO's fleet fueling segment expects to leverage its leading marketing and operations knowledge to manage fleet fueling sites and create value for customers. ARKO's agreement to acquire WTG's convenience store, fleet fueling business and independent dealer locations is the Company's fourth announced acquisition of 2022. Together with the recently announced Pride Convenience Holdings and Transit Energy Group transactions, the acquisition of WTG's assets highlights the Company's systematic growth strategy designed to increase the Company's cash flow and Adjusted EBITDA. Combined, WTG, Pride, and TEG are expected to grow the Company's base of convenience stores by approximately 15%, adding over 200 retail stores and a pipeline of new build opportunities. WTG would greatly expand ARKO's highly accretive fleet fueling segment, growing from 183 sites at the end of the third quarter of 2022 to over 290 upon closing. WTG sold approximately 85.0 million total gallons in FY 2021 across their stores, fleet fueling and independent dealer locations. The total purchase price for WTG is approximately $140.4 million plus the value of inventory at closing. ARKO intends to finance from its own sources approximately $25.4 million of the cash consideration plus the value of inventory and other closing adjustments. The remaining approximately $115 million is expected to be funded by Oak Street Real Estate Capital, a Division of Blue Owl Capital as part of the existing $1.15 billion agreement with the Company, according to which Oak Street is expected to acquire certain real estate assets of WTG as part of the transaction. The Company would lease such real estate assets from Oak Street. Using estimated forward-looking non-GAAP measures, the Company expects that this acquisition will add approximately $10.6 million of Adjusted EBITDA on an annual run rate, after incremental annual rent of approximately $6.9 million to be paid to Oak Street for the forementioned leases. The closing of the transaction is subject to fulfillment of conditions precedent. There is no certainty that the transaction will close.

07:05 EST Prometheus announces results for PRA023 in APOLLO-CD Phase 2 study - Prometheus Biosciences reported results from its ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies of PRA023 demonstrating strong efficacy and favorable safety results in both studies. Based on the totality of the data in these two studies, Prometheus intends to advance PRA023 into Phase 3 studies for ulcerative colitis and Crohn's disease in 2023. Results from the APOLLO-CD Phase 2a Study: Prometheus' Phase 2a APOLLO-CD clinical trial was a 12-week open-label study that enrolled 55 patients with moderate-to-severely active CD with endoscopically active disease who had failed conventional or biologic therapy. The study enrolled a highly refractory patient population with 70.9% of patients previously treated with at least one biologic therapy and 52.7% treated with two or more biologic therapies. The results on the key endpoints were as follows: 26.0% of patients on PRA023 achieved endoscopic response; 49.1% of patients on PRA023 achieved clinical remission; PRA023 was well tolerated in the APOLLO-CD study. There were no treatment-emergent serious adverse events, adverse events leading to discontinuation, or severe AEs assessed as related to PRA023 by the investigator. The predictive power of the company's prespecified genetic markers was validated using an alternative Crohn's-specific CDx algorithm which showed 45.0% endoscopic response relative to all-comers of 26%. While the original algorithm provided limited benefit on some of the endpoints, the alternative algorithm demonstrated enhanced performance across both clinical and endoscopic outcomes. As a result of these positive data, Prometheus plans to advance PRA023 into pivotal development in 2023, following discussions with regulators.

07:05 EST Lockheed Martin and Sintavia team to advance metal additive manufacturing - Lockheed Martin and Sintavia announced a collaboration to expand research of metal additive manufacturing AM opportunities as an alternative to castings and forgings. AM, also known as 3D printing, has the capability to improve efficiencies in existing castings and forgings supply chains, and provide parts with a higher level of detail and greater design opportunities. Sintavia is an AM supplier to Lockheed Martin, supporting several programs in the manufacture and production of metal additive parts. The new collaboration will explore additional AM technology areas, including laser powder bed fusion, electron beam-directed energy deposition and friction stir AM. "Sintavia and Lockheed Martin are committed to improving the capability, agility and competitiveness of the defense industrial supply base," said Brian Neff, Sintavia's founder and CEO. "Our partnership with Lockheed Martin seeks to identify and streamline manufacturing inefficiencies, specifically in the production of flight critical structures."

07:04 EST GreenPower Motor announces enhanced partnership with Gemilang International - GreenPower Motor announced an enhanced partnership with Gemilang International to collaborate, develop and market right-hand drive heavy-duty class 4 trucks and vans using GreenPower's EV Star Cargo and EV Star Cab and Chassis to meet the demand of fleet customers across Asia, the Middle East and Europe.

07:02 EST Dana signs agreement with Semikron Danfoss - Dana announced that it has signed a long-term agreement with Semikron Danfoss, one of the world's leading manufacturers of power modules, to secure the supply of silicon-carbide semiconductors, which are designed to be scalable in multiple-chip formats. Targeted for multiple customer programs across the light-vehicle, commercial-vehicle, and off-highway mobility markets, the semiconductors will be used in Dana's silicon-carbide inverter designs, which enable higher system efficiency and power density in a compact package for medium- and high-voltage inverter applications, resulting in the potential for increased range.

06:56 EST State Street announces $500M increase to share repurchases in Q4 - State Street announced an incremental increase of up to $500M to its previously announced fourth quarter common stock share repurchases under the current repurchase authorization previously approved by the company's Board of Directors that expires at the end of 2022. This amount is in addition to the recently completed fourth quarter common share repurchases of $1B. The company now intends to repurchase up to a total of $1.5B of its common stock in the fourth quarter of 2022.

06:47 EST Southwest reinstates 18c per share quarterly cash dividend - Southwest announced that its board of directors, at the close of business yesterday, reinstated and declared a quarterly cash dividend of 18c per share to shareholders of record at the close of business on January 10, 2023, on all shares then issued and outstanding. With the exception of the time period from early 2020 through third quarter 2022, when the company's dividend was suspended due to the uncertainties of the pandemic and the requirements of the company's Coronavirus Aid, Relief, and Economic Security Act financings, the quarterly dividend declared on December 6 represents the company's 175th quarterly dividend dating back more than 40 years. The company's quarterly dividend of 18c per share, or 72c per share annualized, is equivalent to its dividend prior to the pandemic, and amounts to approximately $428M, and an approximate 1.8% dividend yield on an annual basis. The quarterly dividend will be paid on January 31, 2023. Consistent with prior practice, all future dividend determinations are subject to approval by the company's board.

06:36 EST Thor Industries sees FY23 gross profit margin 14.2%-14.9%

06:33 EST BitNile subsidiary announces hosting agreement with Agora Digital - BitNile Holdings (NILE) announced that its wholly owned subsidiary, BitNile, has entered into a hosting agreement securing up to 78 megawatts, or MW, of power with Agora Digital Holdings, a majority-owned subsidiary of Ecoark Holdings (ZEST). Agora Digital will initially provide up to 12 MW of electricity at their digital asset mining hosting facility located in Texas for BNI's use. At BNI's direction and Agora Digital's expense, an additional 66 MW of power can be made available to BNI as determined by BNI, Agora Digital and the electricity provider. Agora Digital is required to raise at least $5M to fulfill obligations under the Agreement to enable the build out of the hosting facility including the initial 12 MW of power. In conjunction with the ongoing expansion of BNI's site in Michigan, the new hosting agreement is intended to maintain BNI's plan to promptly install and operate the Bitcoin miners delivered by Bitmain Technologies. The geographical distribution will also help BNI diversify the risk among its portfolio of mining equipment. BNI believes that the Agreement will enable it to initially power approximately 3,750 S19j Pro miners in the Q1 of 2023.

06:22 EST Ericsson, Aeris sign pact for Accelerator and Connected Vehicle Cloud businesses - Ericsson and Aeris Communications have signed an agreement for the transfer of Ericsson's IoT Accelerator and Connected Vehicle Cloud businesses. Ericsson IoT Accelerator is used by over 9,000 enterprises to manage more than 95M connected devices with 22M eSIM connections globally. These enterprises and connections leverage Ericsson's growing ecosystem of over 35 communications service provider partners for global IoT cellular connectivity. Founded in 1996, Aeris is an expert in the IoT field, providing businesses with intelligent IoT cellular connectivity. Together, Aeris' and Ericsson's IoT platforms will connect over 100M IoT devices worldwide, covering 190 countries.

05:31 EST Turkcell intends to appeal South Africa court decision in MTN case - Turkcell received a decision from the South Gauteng High Court of South Africa stating that Iranian law should be applied to the merits of the dispute and that the Iranian courts have jurisdiction and not the South African courts. Turkcell intends to appeal this decision. "We are surprised and disappointed with the Court's decision preventing a South African company's illegal acts to be subjected to a trial in South Africa" said Serhat Demir, VP of legal and regulation of Turkcell. He added "We are of the opinion that, in the lawsuit, which has been ongoing for almost 10 years regarding the damage caused by MTN by changing the outcome of the tender through bribery and corruption and by illegally interfering license agreement signed with Iran, South African law should be applied and the South African courts should also have jurisdiction over the matter. South Africa is where MTN's headquarter is located and where unlawful acts were planned and took place."

05:26 EST Boeing announces last 747 left the factory ahead of delivery - The last Boeing 747 left the company's widebody factory in advance of its delivery to Atlas Air in early 2023. "For more than half a century, tens of thousands of dedicated Boeing employees have designed and built this magnificent airplane that has truly changed the world. We are proud that this plane will continue to fly across the globe for years to come," said Kim Smith, Boeing VP and general manager, 747 and 767 Programs.

05:21 EST MNG Airlines to become public through Golden Falcon Acquisition combination - MNG Havayollari ve Tasimacilik, or MNG Airlines, a global logistics provider and e-commerce enabler, has entered into a definitive agreement to become publicly traded via a business combination with Golden Falcon Acquisition (GFX), a special purpose acquisition company. The transaction is expected to close in the first half of 2023, after which MNGA will be listed on the New York Stock Exchange under the new ticker symbol (MNGA). As a public company, MNGA is expected to gain increased financial flexibility, and to be well positioned to unlock new growth avenues and maximize value creation. For the three months ended September 30, the company's revenue grew by 47% year-on-year to $90M, net income of $26M and adjusted EBITDA of $27M. Last twelve months revenue grew by 39% year-on-year to $353M, net income of $61 million and Adjusted EBITDA of $116M. Adjusted EBITDA margin for the last twelve months has improved by 400 basis points as compared with 2019, and revenue has grown at a 37% compound annual growth rate during this period. The company's business model has four segments: Scheduled & Block Space, Charter, ACMI7, and Warehouse & Handling. The company's cost base is mostly variable, with cost of goods sold representing 95% of its overall cost base in 2021. Company contracts have limited exposure to fuel costs, which are either 100% pass-through to the end customer or updated every two weeks. Revenues are generated in USD, EUR and GBP, collectively accounting for 98% of the total. The company has been net income-positive for the last 10 years. The company has net debt of $25M as of September 30. The transaction is expected to have a pro-forma enterprise value of $676M, assuming minimum gross transaction proceeds of $30M, implying a 5.8x multiple on LTM Adjusted EBITDA as of September 30. All references to available cash from the trust account and retained transaction proceeds are subject to any redemptions by the public stockholders of Golden Falcon. The company benefits from significant positive cash flow generation and a capex-light business model, being able to organically fund its growth plans. Its current business plan is fully funded regardless of transaction proceeds. Net proceeds from the transaction will therefore be distributed to the company's existing shareholders, who are expected to continue to retain a significant stake in the company. The Golden Falcon management team screened over 500 potential targets since its IPO in December 2020. Prior to executing the business combination agreement with MNGA, the Golden Falcon team conducted extensive due diligence throughout the course of the past ten months, supported by its advisor UBS Investment Bank. In order to closely align incentives with the company and existing shareholders, the Golden Falcon team has agreed to subject over 90% of sponsor shares received as merger consideration to a vesting schedule. The proposed business combination, which has been unanimously approved by both the board of directors of Golden Falcon and the board of directors of MNGA, is expected to close in the first half of 2023, subject to approval by Golden Falcon's stockholders and other customary closing conditions. Subject to agreement on terms that are satisfactory to the company and Golden Falcon, in order to provide certain redemption alternatives in connection with Golden Falcon's stockholder vote to approve the business combination, the company and Golden Falcon intend to make available to Golden Falcon stockholders some or all of the following options: continue to hold their shares of Golden Falcon Class A Common Stock, elect to redeem their shares of common stock in accordance with the Golden Falcon Certificate of Incorporation or convert their shares of common stock into a newly issued security to be comprised of a combination of shares of common stock and convertible notes. The company and Golden Falcon intend for the newly issued security referred to in above to entitle such Golden Falcon stockholder to receive a portion of the value of its shares in the form of shares of Common Stock and a portion in the form of registered convertible notes, with both a cash coupon, a conversion premium, and other material terms that are expected to be mutually agreed by the company and Golden Falcon.

05:08 EST Jacobs awarded contract to support U.K.'s fusion energy research program - Jacobs was awarded a contract to support the U.K.'s fusion energy research program. The United Kingdom Atomic Energy Authority, or UKAEA, has appointed the company on all lots of its new Plant Maintenance and Operational Support Services, or PMOSS, framework. Subject to competition under the framework, Jacobs' project delivery professionals will be embedded in client teams at UKAEA, the U.K.'s national fusion laboratory, to work on some of the world's most advanced research into machine design, robotics, materials science and fusion fuel.